MAP2K7 and neurofibromatosis type 1: A recent exciting development is the FDA approval of the MEK inhibitor selumetinib (KoselugoTM) for the treatment of children with symptomatic, inoperable PNF based on the trial (ClinicalTrials.gov Identifier: NCT01362803) which demonstrated a 72% response rate in tumor volume shrinkage by ≥20% in NF1 children with PNFs (11).